Targeting treatment specifically to the liver improved safety while maintaining benefit.
In a London laboratory, scientists have done what medicine could not before — coaxed a dying liver back to life by delivering a single missing gene with surgical precision. The work, emerging from UCL and Great Ormond Street Hospital, addresses ARC syndrome, a condition so rare and so lethal that most of its youngest victims do not live to see their first birthday. Though human trials remain years away, the research establishes something quietly profound: that in gene therapy, the architecture of delivery may matter as much as the message itself.
- ARC syndrome kills nearly every child it touches before age one, and until now no treatment of any kind has existed to interrupt that outcome.
- Early versions of the gene therapy worked — but roughly a third of treated mice developed liver tumors, raising the alarm that the cure risked becoming its own catastrophe.
- Researchers narrowed their aim, targeting the therapy exclusively to liver cells rather than the whole body, and the tumors disappeared entirely while the survival benefit held.
- Treated mice survived at an 80% rate compared to 33% in untreated animals, with healthier livers and dramatically less scarring — a result that reframes what is possible.
- The road to human trials is still long, gated by toxicology studies and safety monitoring, but for roughly six UK families each year facing this diagnosis, a door has opened that was not there before.
Researchers at University College London and Great Ormond Street Hospital have achieved the first successful treatment of ARC syndrome in mice — a milestone for one of pediatric medicine's most devastating diagnoses. ARC syndrome, caused by the absence of a single protein called VPS33B, prevents the liver from regulating bile flow. Bile accumulates, spills into the bloodstream, and triggers a cascade of organ failure that is almost universally fatal before a child's first birthday. In the UK, around six pregnancies each year carry the diagnosis. There are no existing treatments.
The team engineered mice to replicate the disease and injected a healthy copy of the VPS33B gene directly into their bodies. Survival rates climbed to roughly 80 percent, compared to one-third among untreated animals, and treated livers showed far less scarring. But the early approach carried a serious flaw — about 30 percent of treated mice developed liver tumors, a known hazard when inserted genes become overactive and trigger malignant growth.
The decisive refinement was precision. By targeting the therapy specifically to liver cells rather than dispersing it throughout the body, the team eliminated tumor development entirely without sacrificing the treatment's benefit. The insight reaches beyond ARC syndrome: how a gene therapy is delivered, and where, shapes its safety as fundamentally as which gene it carries. Lead author Dr. Claudiu Cozmescu noted the work opens a path for other inherited liver diseases currently beyond medicine's reach, while co-author Professor Paul Gissen observed that even the tumor-prone early versions taught a critical lesson — keeping inserted gene levels close to those found in healthy cells appears essential to preventing cancer.
Human trials remain years away, contingent on extensive safety studies. But for families confronting an ARC syndrome diagnosis, the research offers something that has never existed before: a credible reason to hope.
A team of researchers at University College London and Great Ormond Street Hospital has demonstrated that a targeted gene therapy can reverse the effects of ARC syndrome in mice—a rare but catastrophic childhood liver disease that typically claims infants before their first birthday. The work, published in Nature Communications, represents the first successful treatment of the condition and offers a potential path forward for families facing one of pediatrics' most unforgiving diagnoses.
ARC syndrome, short for arthrogryposis, renal dysfunction and cholestasis, is caused by the absence or malfunction of a single protein called VPS33B. Without it, the liver cannot properly regulate the flow of bile—the digestive fluid that breaks down fats. Bile backs up in the liver and spills into the bloodstream, where its toxic components accumulate and trigger sepsis, a cascade of organ failure that is almost always fatal. In the United Kingdom alone, roughly six pregnancies each year result in a diagnosis of ARC syndrome. There are currently no effective treatments.
The researchers created mice genetically engineered to lack functional VPS33B genes, replicating the disease as it appears in human infants. They then injected a healthy version of the gene directly into the animals' bodies. The results were striking: about 80 percent of treated mice survived, compared with roughly one-third of untreated controls. The livers of treated animals showed significantly less scarring and resumed normal function. But the early versions of the therapy came with a troubling cost. Around 30 percent of the mice developed liver tumors—a known risk of gene therapy in which inserted genes become abnormally active and trigger cancerous growth.
The breakthrough came when the team refined their approach to target the therapy specifically to liver cells rather than distributing it throughout the entire body. This precision proved decisive. None of the mice receiving the final, liver-targeted version developed tumors, while maintaining the therapeutic benefit. The finding illuminates a principle that extends far beyond ARC syndrome: the design of a gene therapy—not just what gene is delivered, but how and where it is delivered—fundamentally shapes both its safety and its effectiveness.
Dr. Claudiu Cozmescu, the lead author, emphasized that the work provides proof of concept for treating not only ARC syndrome but potentially other inherited liver diseases for which current medicine offers little hope. Professor Paul Gissen, a co-author, noted that the earlier, tumor-prone versions of the treatment actually yielded valuable insights: keeping the levels of inserted genes as close as possible to those found in healthy cells appears to be critical to preventing malignant transformation.
The path from mouse to human remains long. Researchers must conduct extensive toxicology studies and long-term safety monitoring before any human trials can begin. But for families who have received an ARC syndrome diagnosis, the work represents something that has been absent until now: a realistic possibility that their child might survive.
Citações Notáveis
Our findings provide proof of concept that gene therapy could become a realistic treatment for ARC syndrome and potentially other inherited liver diseases that currently have few or no effective options.— Dr. Claudiu Cozmescu, lead researcher at UCL Great Ormond Street Institute of Child Health
One of these insights is to keep the levels of genes as close to those found in healthy cells as possible.— Professor Paul Gissen, clinical professor of pediatric metabolic medicine at UCL
A Conversa do Hearth Outra perspectiva sobre a história
Why does the location where the gene lands matter so much? The gene is the same either way.
Because context is everything in biology. When the gene was distributed throughout the body, it got activated in places where it shouldn't be, at levels higher than normal. The liver cells couldn't handle that. But when you deliver it only to liver cells, you're working within a system that already knows how to use that protein. You're restoring balance, not creating chaos.
So the tumors in the early trials—were those a failure, or did they teach something?
Both. They were a setback, obviously. But they revealed something crucial about how gene therapy can go wrong. The team learned that you can't just inject a gene and hope. You have to think like an engineer: precision matters. Targeting matters. That knowledge will help with other diseases too.
Six pregnancies a year in the UK. That's not many. Why invest so much effort in something so rare?
Because those six families face a choice between watching their child die or having no choice at all. And because the science here—the principles about how to deliver genes safely—applies to dozens of other rare liver diseases. You solve one, you learn how to solve others.
When do you think this will actually be available to patients?
Years away, at minimum. The mice are cured, but mice aren't people. You need to prove it's safe in humans, and that takes time. But for the first time, there's a real path. That changes everything for families living with this diagnosis.